CG Oncology, Inc. announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS). The data will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting from May 31-June 4, in Chicago, IL.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.78 USD | +2.99% |
|
+17.19% | 0.00% |
Jun. 28 | Sector Update: Health Care Stocks Decline in Late Afternoon Trading | MT |
Jun. 28 | Sector Update: Health Care Stocks Edge Higher in Afternoon Trading | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 2.51B | |
+22.60% | 47.96B | |
+0.72% | 42.45B | |
+43.79% | 41.47B | |
+27.33% | 31.6B | |
+20.72% | 28.63B | |
-6.35% | 28.03B | |
+52.71% | 14.56B | |
+43.89% | 14.14B | |
+2.97% | 12.58B |
- Stock Market
- Equities
- CGON Stock
- News CG Oncology, Inc.
- CG Oncology, Inc. to Present Positive Final Results from Phase 2 Core-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC At Asco 2024 Annual Meeting